Statistical Considerations for Clinical Trials During COVID-19: Independent DMC for Blinded Data Monitoring and Analysis

Qing Liu, Karl E. Peace

Research output: Contribution to journalArticlepeer-review

Abstract

To supplement both the FDA and EMA guidance, we describe the principles and key elements for developing a DMC chart for individual clinical trials affected by COVID-19.

Original languageAmerican English
JournalLinkedIn
StatePublished - Apr 21 2020

DC Disciplines

  • Biostatistics
  • Environmental Public Health
  • Epidemiology
  • Public Health

Fingerprint

Dive into the research topics of 'Statistical Considerations for Clinical Trials During COVID-19: Independent DMC for Blinded Data Monitoring and Analysis'. Together they form a unique fingerprint.

Cite this